← Leaderboards
Flavio Vincenti
University Of California San Francisco
$15,185,072
Attributed
$15,185,072
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.4M · FY2005–23$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$15,185,072 · 2
By mechanism
U01$15,179,927 · 1
M01$5,145 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Alan S Go$41,264,928
- Nicholas M Barbaro$8,817,398
- Russell O Pieper$18,535,472
- William L Young$17,255,273
- Anna-Barbara None Moscicki$36,508,762
Others in their field
Top investigators on “Chronic”
- Judith S. Currier · University Of California Los Angeles$245,012,139
- Lawrence Corey · Fred Hutchinson Cancer Center$209,947,290
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$201,828,077
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$173,476,538
- John M Lachin · George Washington University$125,152,883
- David M Nathan · Massachusetts Institute Of Technology$120,438,756
Research focus
ChronicTransplant RecipientsKidneyCellsResponseT-LymphocyteGraft SurvivalInterleukin 6 ReceptorPreventPathway InteractionsRandomizedRegimenAntibodiesSafetyAntigensCessation Of LifeAutologousInfusion ProceduresMediatingKidney TransplantationOrgan TransplantationBaseNovel TherapeuticsBiopsy
Grant awards (11)
Applying precision MEdicine to optimize desensitization with noveL bIOlogics or cellular theRApies in highly sensiTized kidney transplant patiEnts (AMELIORATE)$634,397
U01 · FY2023 · AI · contact PI
Applying precision MEdicine to optimize desensitization with noveL bIOlogics or cellular theRApies in highly sensiTized kidney transplant patiEnts (AMELIORATE)$819,899
U01 · FY2022 · AI · contact PI
Applying precision MEdicine to optimize desensitization with noveL bIOlogics or cellular theRApies in highly sensiTized kidney transplant patiEnts (AMELIORATE)$1
U01 · FY2021 · AI · contact PI
Novel Therapies to Modulate the Inflammatory Alloresponse in Renal Grafts$559,395
U01 · FY2020 · AI · contact PI
Novel Therapies to Modulate the Inflammatory Alloresponse in Renal Grafts$1,259,989
U01 · FY2019 · AI · contact PI
Novel Therapies to Modulate the Inflammatory Alloresponse in Renal Grafts$2,339,148
U01 · FY2018 · AI · contact PI
Novel Therapies to Modulate the Inflammatory Alloresponse in Renal Grafts$2,370,047
U01 · FY2017 · AI · contact PI
Novel Therapies to Modulate the Inflammatory Alloresponse in Renal Grafts$2,383,582
U01 · FY2016 · AI · contact PI
Novel Therapies to Modulate the Inflammatory Alloresponse in Renal Grafts$2,394,018
U01 · FY2015 · AI · contact PI
Novel Therapies to Modulate the Inflammatory Alloresponse in Renal Grafts$2,419,451
U01 · FY2014 · AI · contact PI
THE EFFECT OF RITUXIMAB ON THE DEVELOPMENT OF ANTI DONOR ANTIBODIES AND RESOL$5,145
M01 · FY2005 · RR